Welcome to the OMA Blog
The Obesity Medicine Association Blog is the leading industry hub for obesity medicine. Find the latest research, expert insights, and practical tips to tackle the multifaceted disease of obesity. Hear from OMA Outreach Committee members, OMA Board members, and more to gain a deeper understanding of the complex factors influencing obesity and explore innovative approaches to prevention, treatment, and long-term management. Join a community of healthcare professionals, researchers, and individuals passionate about combating obesity.
View by Category
COVID-19 Vaccine and BMI
As the COVID-19 pandemic has progressed, we have learned much about the virus, the disease process, its complications and management, and who is most severely…
OMA President-Elect Responds to Dr. Akshay B Jain’s article, “Obesity and the Bitter Pill of Truth”
The Obesity Medicine Association (OMA) would like to commend Dr. Akshay B. Jain on the excellent article in Medscape , “Obesity and the Bitter Pill…
Antihistamines and Weight Gain
Benadryl, Allegra, Zyrtec, Claritin are all antihistamines sold throughout the United States, both over the counter and via prescription. Anyone who suffers from chronic sinus…
FDA – Belviq Announcement
What does the FDA’s Belviq announcement mean? The FDA has requested the removal of Belviq (lorcaserin), a weight-loss medicine approved by the FDA in 2012,…
Dr. Wendy Scinta, OMA President, Featured in Advances in Therapy
Wendy Scinta, MD, MS, FOMA, who is the president of the Obesity Medicine Association and an obesity medicine physician in Fayetteville, N.Y., contributed to the…
Medications That May Increase Weight
Many commonly used medications may cause weight gain. The amount of weight gained may vary depending on the patient and type of medication. Mechanisms for…
Obesity Medications
Anti-obesity medications are a class of medications that have a primary indication for the treatment of obesity. Obesity is a multi-factorial chronic disease and like other…
The Treatment of Obesity – FDA Approves BELVIQ XR ER
On July 19, Eisai, Inc., and Arena Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration (FDA) approved BELVIQ XR (lorcaserin HCl) CIV extended-release…
Showing 10-17 of 17 results